The Comparison of Serum Antibody Response to Standard Intramuscular and Half Dose Intradermal Influenza Vaccine in Hemodialysis Patients in Shiraz City in 1388.
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Hemodialysis Patients
- Sponsor
- Shiraz University of Medical Sciences
- Enrollment
- 130
- Locations
- 1
- Primary Endpoint
- vaccine effectiveness
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to determine whether half-dose intradermal influenza vaccine is as immunogenic as standard dose intramuscular vaccine in hemodialysis patients.
Detailed Description
Hemodialysis patients are at high risk of influenza infection due to suppress immune status.It is recommended to immunize them against influenza annually.in intradermal vaccination antigens directly present to the large numbers of antigen-presenting cells in the skin and it may cause greater immunogenicity than in the intramuscular method. Reduced-dose intradermal influenza vaccine is immunogenic in healthy adult, patients with solid cancer and three groups of immunocompromized patients including Rheumatologic patients treated with anti-TNF, HIV-infected and stem cell transplanted patients. In this study we compare the efficacy of influenza vaccines in half dose intradermal and standard intramuscular methods among hemodialysis patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients under chronic hemodialysis
Exclusion Criteria
- •history of flu infection in last month
- •history of flu vaccination in 2009
- •hospitalization in last month
- •taking immune suppressants drugs
- •hemodialysis less than twice weekly
Outcomes
Primary Outcomes
vaccine effectiveness
Time Frame: 3 months
serum antibody response measured by ELIZA method time frame:1 and 3 months after vaccination